Table 3.
Base case results of the cost-effectiveness analysis.
| Treatment | Cost (CNY) | QALYs | Incremental Cost (CNY) | Incremental QALYs | ICER |
|---|---|---|---|---|---|
| Dacomitinib | 265,512 | 1.9548 | |||
| Gefitinib | 247,048 | 1.6067 | 18,463 | 0.3132 | 58,947 |
CNY, Chinese Yuan; QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio.